Pan-cancer multi-omics profiling of OAS3 reveals its immunological and prognostic associations across human cancers

Xi Zhang, Hongyan Zhang, Liang Zhong, Wei Yang, Chunhui Yang, Yuqing Pan, Beizhong LiuPeerJ 2026 · DOI

TL;DR

This study provides a comprehensive pan-cancer analysis of OAS3, a gene involved in innate immunity, revealing its complex and context-dependent roles in cancer progression. The findings highlight OAS3's significant associations with tumor immunity, prognosis, and molecular characteristics across various cancer types, suggesting its potential as a therapeutic target.

What Problem Does This Paper Address?

While OAS3 is known for its role in antiviral immunity, its involvement in cancer biology remains largely unexplored. Cancer is a complex disease driven by accumulating genetic alterations that disrupt normal cellular functions, leading to uncontrolled proliferation and immune evasion. Understanding the molecular mechanisms that govern cancer progression and immune response is crucial for developing effective therapies. This paper aims to fill this knowledge gap by comprehensively investigating OAS3's expression patterns, mutation characteristics, prognostic significance, and its interplay with the tumor microenvironment across a wide range of human cancers.

Methods

The researchers employed a multi-omics approach, leveraging publicly available cancer datasets. Key methods included:

  • Differential Expression Analysis: Comparing OAS3 expression in tumor versus normal tissues across various cancer types using R software and the Human Protein Atlas.
  • Prognostic Analysis: Utilizing Cox proportional hazards regression and Kaplan-Meier survival analysis on TCGA and TARGET datasets to assess the correlation between OAS3 expression and patient survival (overall survival and disease-free survival).
  • Immune Correlation Analysis: Investigating the association between OAS3 expression and immune-related genes, immune checkpoints, and immune cell infiltration using Spearman's rank-order correlation and various bioinformatics tools (e.g., ESTIMATE, TIMER2.0, xCell, CIBERSORT).
  • Pathway Enrichment Analysis: Employing Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways to understand the functional roles of OAS3-associated genes.
  • Mutation Analysis: Examining OAS3 mutation frequencies and their correlation with genomic features like homologous recombination deficiency (HRD) and tumor mutational burden (TMB) using the cBioPortal platform.
  • Functional Validation: In vitro experiments using THP-1 cells to assess the impact of OAS3 knockdown on apoptosis via flow cytometry.

Datasets

The study primarily utilized data from the following public repositories:

  • UCSC Xena Browser: Integrated data from The Cancer Genome Atlas (TCGA), Therapeutically Applicable Research to Generate Effective Treatments (TARGET), and Genotype-Tissue Expression (GTEx) projects.
  • Human Protein Atlas (HPA): For mRNA expression levels in normal human tissues.
  • Gene Expression Profiling Interactive Analysis (GEPIA2): For stage-specific expression analysis.
  • cBioPortal: For mutation analysis and genetic alteration patterns.
  • CancerSEA: For analyzing functional characteristics of OAS3 in tumor cells.
  • LinkedOmics: For identifying gene networks associated with OAS3.
  • KMplot database: For survival analysis in specific mutation contexts.

No new benchmark datasets were introduced.

Key Insights and Ideas

  • OAS3 is a double-edged sword: Its expression is not uniformly good or bad; it can act as an oncogene in some cancers and a tumor suppressor in others, highlighting its context-dependent nature.
  • Immune Modulation is Key: OAS3's strong correlations with immune-related genes, checkpoints, and various immune cell types suggest a significant role in shaping the tumor immune microenvironment.
  • Stemness Connection: OAS3's association with cancer stemness pathways (like JAK-STAT and Notch) points to its potential involvement in tumor self-renewal and resistance mechanisms.
  • Prognostic Heterogeneity: While high OAS3 expression is linked to poorer survival in many cancers, it's associated with improved survival in others, underscoring the need for cancer-type-specific analyses.

Key Results

  • Upregulation in Most Cancers: OAS3 was significantly upregulated in 32 out of 34 cancer types analyzed, with stage-specific expression patterns observed in several.
  • Prognostic Significance: High OAS3 expression was associated with poorer overall survival (OS) in cancers like GBMLGG, LGG, LAML, KIPAN, ACC, PAAD, and LUAD, but with improved survival in SKCM.
  • Immune Correlations: OAS3 showed significant positive correlations with chemokines, receptors, and immune checkpoint molecules, suggesting its role in immune cell recruitment and regulation. It was also positively correlated with M1 macrophages and Th2 cells.
  • Mutation Hotspots: OAS3 exhibited high mutation frequencies in endometrial cancer and melanoma.
  • Functional Roles: Pathway enrichment analysis indicated OAS3's involvement in interferon response, JAK-STAT signaling, and Notch signaling pathways. In lung and breast cancer, it was linked to cell cycle regulation and DNA damage.
  • Apoptosis Induction: Knockdown of OAS3 in THP-1 leukemia cells significantly increased apoptosis, suggesting its role in cell survival.

Limitations and Future Work

The authors acknowledge several limitations:

  • No Batch-Effect Correction: While trends were consistent, dedicated batch-effect correction methods could refine findings.
  • Limited Matched Normal Tissues: This restricted the ability to evaluate baseline OAS3 expression differences in some TCGA cohorts.
  • Bulk Sequencing Data: Associations may reflect combined signals from tumor, immune, or stromal compartments, necessitating single-cell or spatial transcriptomic validation.
  • Correlative Nature: Many findings are correlative, and further mechanistic studies are required to establish direct functional roles and therapeutic relevance.

Future work should focus on:

  • Mechanistic Studies: Elucidating the precise molecular mechanisms by which OAS3 influences tumor development and immune responses.
  • In Vivo Validation: Conducting animal studies to confirm therapeutic potential.
  • Single-cell/Spatial Transcriptomics: To pinpoint OAS3's cellular origin and specific functions within the tumor microenvironment.
  • Cancer-Specific Stratified Analyses: To gain deeper insights into the context-dependent roles of OAS3.

Summary updated

Abstract

This study demonstrates that OAS3 acts as a pivotal modulator in the complex network of cancer progression, highlighting its dual role in both tumorigenesis and immune response regulation.
BibTeX
@inproceedings{zhang2026pan,
  author = {Xi Zhang and Hongyan Zhang and Liang Zhong and Wei Yang and Chunhui Yang and Yuqing Pan and Beizhong Liu},
  title = {{Pan-cancer multi-omics profiling of OAS3 reveals its immunological and prognostic associations across human cancers}},
  booktitle = {PeerJ},
  year = {2026},
  doi = {10.7717/peerj.20805},
}
Figure